-
Teva Pharmacueticals Has Superior Market Strategy (Peer Reviewed Scholarly Article)
Teva pharmaceuticals is a global company with a superior strategy of "market takeover", as opposed to local company's strategies of simply prevailing in the marketplace. -
Perrigo acquires Omega Pharma Invest
Perrigo Company plc acquires Omega Pharma Invest N.V. -
Teva Proposes Buyout (Trade Journal Article)
Teva proposes a deal to purchase Mylan for ~$50 million. -
Dr. Reddy's Laboratories signs commercialization deal with Hatchtech
Dr. Reddy’s Laboratories (NYSE: RDY) today announced the signing of a commercialization deal with Hatchtech, an Australian pharmaceutical company developing an innovative prescription head lice product, Xeglyze™ Lotion. -
IBM Watson Health and Teva Pharmaceuticals Partner (Trade Article)
IBM Watson Health Cloud and Teva Pharmaceuticals partner to form the first global pharmaceutical partnership with Watson Health Cloud to benefit healthcare providers and patients -
Dr. Reddy Laboratories recieve warning from USFDA
DRL received warning letters from the U.S. Food and Drug Administration authorities in November 2015 regarding inadequate quality control procedures at 3 manufacturing plants in India -
Mylan reminds Perrigo Shareholders of Buyout Expiration
Nov 10, 2015 - Mylan reminds shareholders of Perrigo that its offer to acquire all outstanding shares of Perrigo will expire -
Joseph Papa leaves Perrigo
Chief Executive Joseph Papa leaves months after he helped Perrigo beat back a hostile bid from Mylan -
Mylan Futures Up (Regional Business Article)
Mylan Futures up 4% in second quarter -
Dr. Reddy's acquired six OTC brands from Ducere Pharma
Drug major Dr Reddy's Laboratories has forayed into branded consumer health products segment in the US market by acquiring six over-the-counter (OTC) brands from Ducere Pharma for an undisclosed amount. The brands acquired include Doan's, Bufferin, Nupercainal ointment, Cruex nail gel, comtrex and myoflex. These are mainly used in treating cough-and-cold, pain and dermatology issues. -
Zack's Investment Research Rates Teva Pharmaceuticals with a Hold Grade (Regional Article)
Zack's Investment Research rated Teva Pharmaceuticals down to a "sell" rating from a "hold" rating, saying the company is expected to start going downwards -
Mylan Commits to Increased Access (Press Release)
Mylan commits to providing EpiPen to as many people for as cheap as possible -
Class Action Lawsuit against Perrigo
Pomerantz LLP announces a class action lawsuit has been filed against Perrigo Company -
Dr. Reddy's gets approval to export 15 drugs to EU
Hyderabad-based pharmaceutical company Dr Reddy’s Laboratories has received approval from the Central Drug Standard Control Organization (CDSCO) to export drugs for the European Union market. In an order dated August 5, CDSCO gave its nod, which will allow Dr Reddy’s to export port 15 active pharmaceutical ingredients (APIs) to the European Union. These drugs are used to treat hypertension, pneumonia, bacterial infection, cardiovascular diseases, migraine, among others. -
Dr. Reddy's acquires Teva's eight US products
Dr Reddy's announced that it has successfully completed the acquisition of eight Abbreviated New Drug Applications (ANDAs) in the US from Teva Pharmaceuticals Industries and an affiliate of Allergan Plc. The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of acquisition of Allergan's generics business. In June, the company had entered an agreement with Teva to buy this portfolio of ANDAs for $ 350 million. -
Justice Department Conducts Investigation on Antitrust Allegations (Press Release)
Justice Department is conducting an antitrust violation investigation against over a dozen pharmaceutical companies, including Teva Pharmaceuticals; shares of Lannett fell in value after this was announced by Bloomberg -
Mylan Conflict of Interest (Peer Reviewed Scholarly Article)
Mylan shareholder manipulates market to profit off of merger, risking conflict of interest concerns. (Peer Reviewed Scholarly Article)